Compare · MDT vs QTI
MDT vs QTI
Side-by-side comparison of Medtronic plc. (MDT) and QT Imaging Holdings Inc. (QTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and QTI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $130.88B, about 5271.1x QTI ($24.8M).
- MDT has been more active in the news (14 items in the past 4 weeks vs 9 for QTI).
- MDT has more recent analyst coverage (25 ratings vs 0 for QTI).
- Company
- Medtronic plc.
- QT Imaging Holdings Inc.
- Price
- -
- -
- Market cap
- $130.88B
- $24.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 9
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
- Medtronic upgraded by Piper Sandler with a new price target
- Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
- Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
Latest QTI
- QT Imaging to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
- QT Imaging Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by QT Imaging Holdings Inc.
- QT Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- QT Imaging Reports 75% Third Quarter Revenue Growth and Major Medicare Reimbursement Milestone
- QT Imaging Secures First GCC Commercial Order from American Hospital Dubai, Plans Clinical Research Collaboration
- QT Imaging Secures Medicare Outpatient Reimbursement for QTscan®, Effective January 2027
- QT Imaging to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- QT Imaging to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
- QT Imaging’s Breast Acoustic CT™ Scanner Now Available Through National Group Purchasing Agreement with Premier